Mounjaro Cost in California 2026: Cash Price, Insurance, and Compounded Options

What Is the Actual Mounjaro Price in California Right Now?

The Eli Lilly wholesale acquisition cost for Mounjaro in 2026 is $1,023 per month regardless of dose, and California retail pharmacies pass that price through almost directly to uninsured cash-pay patients. A 2025 GoodRx analysis found that the spread between the lowest and highest California retail quotes for a 4-pen carton of any tirzepatide dose sits within roughly $30 of that $1,023 figure, meaning discount aggregators provide minimal savings on the branded product itself.

Dose does not change the price. Whether a patient fills 2.5 mg, 5 mg, 10 mg, or 15 mg, the monthly cost stays fixed at the same list price, because Eli Lilly prices all Mounjaro doses identically. That pricing structure differs from insulin analogues, where higher-concentration vials carry a separate price tier.

The FDA approved tirzepatide for type 2 diabetes under the brand name Mounjaro in May 2022 [1]. The same molecule received a separate FDA approval for chronic weight management as Zepbound in November 2023 [2]. California prescribers writing for weight loss without a diabetes diagnosis must technically prescribe Zepbound, not Mounjaro, though the active ingredient is identical.

SURPASS-2 (N=1,879, published in NEJM 2021) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg over 40 weeks [3]. Tirzepatide 15 mg produced a mean HbA1c reduction of 2.46% and a mean body weight reduction of 9.5 kg, compared with 1.86% and 5.4 kg for semaglutide 1 mg (P<0.001 for both comparisons) [3]. Those glycemic and weight outcomes are the clinical backbone behind the medication's high demand and, consequently, its elevated price point.

Does Medi-Cal Cover Mounjaro in California?

Medi-Cal covers Mounjaro for type 2 diabetes when a prior authorization (PA) request is approved. The coverage does not automatically extend to off-label weight-loss use in patients without a diabetes diagnosis.

To obtain a PA under Medi-Cal fee-for-service, a prescriber typically documents a confirmed type 2 diabetes diagnosis using ICD-10 code E11.x, evidence of inadequate glycemic control on at least one first-line agent (most commonly metformin), and a clinical rationale for tirzepatide over less expensive alternatives such as sulfonylureas or SGLT-2 inhibitors. Processing time for PA requests runs 3 to 5 business days for standard reviews and 24 hours for expedited urgent requests under California Department of Health Care Services rules [4].

Medi-Cal managed care plans (Anthem, Blue Shield Promise, Health Net, Molina, and others) each maintain their own formulary tiers but are required to cover drugs approved under the Medi-Cal fee-for-service formulary when medically necessary. Some plans have placed tirzepatide on a specialty tier requiring step therapy through GLP-1 receptor agonists such as liraglutide or semaglutide 0.5 mg before approving Mounjaro. Patients denied at that step may request a formulary exception citing the SURPASS-2 head-to-head data [3].

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists and GIP/GLP-1 dual agonists as second-line therapy when additional weight reduction is a clinical priority alongside glucose lowering [5]. Citing that guideline language directly in a PA letter strengthens the clinical argument for Mounjaro over older agents.

Medi-Cal does not currently cover Zepbound (tirzepatide for obesity) under the obesity carve-in enacted in January 2024, because that benefit expansion applies to semaglutide 2.4 mg (Wegovy) and selected other weight-loss agents under a separate drug-class coverage determination. A prescriber seeking tirzepatide coverage for a Medi-Cal patient who has obesity but not diabetes may need to document a comorbidity such as obstructive sleep apnea, hypertension, or dyslipidemia and appeal under medical necessity.

Is Compounded Tirzepatide Legal in California?

Compounded tirzepatide from a 503A pharmacy is currently legal in California, subject to California State Board of Pharmacy oversight and a valid patient-specific prescription. The operative word is currently: the regulatory picture has shifted more than once in the past 24 months and may shift again.

The FDA placed tirzepatide on its drug shortage list in 2023 and removed it from that list in March 2025. During the shortage period, 503A pharmacies could legally compound tirzepatide under 21 U.S.C. 503A because FDA policy permits compounding of drugs that appear on the shortage list or that are not commercially available in the strength prescribed [6]. Once the FDA removed tirzepatide from the shortage list, 503B outsourcing facilities lost their blanket authority to compound it. However, 503A pharmacies retained the ability to compound tirzepatide for individual patients when a licensed prescriber submits a patient-specific prescription and the pharmacy does not make the compound in anticipation of prescriptions (i.e., no pre-compounding in bulk for office stock) [6].

In California specifically, the State Board of Pharmacy requires 503A pharmacies to compound under USP <797> sterile compounding standards for any injectable preparation. A patient or prescriber can verify a pharmacy's 503A status and sterile compounding license at the California BreEZe license lookup portal. Purchasing compounded tirzepatide from an unlicensed online vendor, a foreign pharmacy, or a facility without a California 503A designation is illegal and carries documented safety risks including variable potency and contamination [7].

Compounded tirzepatide at California-licensed 503A pharmacies averages roughly $249 per month, representing a 76% cost reduction versus the branded list price. That figure assumes a mid-range maintenance dose; some pharmacies price by vial concentration, so actual cost varies with prescribed dose.

The HealthRX prescriber team uses a three-question framework before recommending a compounding pharmacy to a California patient: (1) Does the pharmacy hold an active California 503A sterile compounding license verifiable on BreEZe? (2) Does the pharmacy provide a Certificate of Analysis (CoA) from an accredited independent testing lab for each lot? (3) Does the pharmacy ship cold-chain with temperature monitors? If any answer is no, the patient should use a different pharmacy.

Which Insurance Plans Cover Mounjaro in California?

Commercial insurance coverage for Mounjaro in California varies by employer plan design, and no state law currently mandates coverage for GLP-1 or GIP/GLP-1 medications across all fully insured plans.

Large employer self-insured plans operating under ERISA have the most latitude to exclude Mounjaro entirely, and a meaningful share have done so since 2023 in response to the drug's cost impact on pharmacy budgets. A 2024 JAMA Internal Medicine analysis found that 35% of large employer plans covering more than 500 lives had implemented a Mounjaro exclusion or required step therapy through two other diabetes agents before approving it [8].

Fully insured individual and small-group plans sold on Covered California are required to comply with California's essential health benefit (EHB) benchmark, which is modeled on the Kaiser Permanente small-group plan. That benchmark covers antidiabetic drugs as a drug class, and tirzepatide qualifies when the indication is type 2 diabetes. Coverage for the weight-loss indication under Covered California plans is less consistent and depends on whether the plan's formulary explicitly lists Zepbound.

Major insurers operating in California and their general Mounjaro tier placement in 2026 include:

• Anthem Blue Cross: specialty tier 4, PA required for type 2 diabetes; Zepbound excluded on most individual plans
• Blue Shield of California: specialty tier, PA required; some employer groups have negotiated preferred placement
• Kaiser Permanente: on formulary for type 2 diabetes with PA; internal step therapy through metformin plus one additional agent first
• Health Net: covered with PA for type 2 diabetes; Zepbound excluded on most plans
• Aetna California: specialty tier, PA required; Zepbound covered on select employer plans with an obesity benefit rider

Patients should call the member services number on the back of their insurance card and ask specifically whether NDC 00002-1435 (a common Mounjaro NDC) is covered, rather than asking generically about "tirzepatide," because the answer can differ by NDC.

How Does the Eli Lilly Savings Card Work for California Residents?

The Eli Lilly Mounjaro savings card reduces out-of-pocket cost to as low as $25 per month for eligible commercially insured California patients. The program is income-independent; eligibility turns on insurance status and diagnosis, not household income.

Key eligibility rules as of 2026:

• The patient must have commercial insurance that covers Mounjaro (even partially).
• Government insurance (Medi-Cal, Medicare Part D, Medi-Cal/Medicare dual eligibility) disqualifies the patient from the savings card under federal anti-kickback rules.
• The diagnosis on the prescription must be type 2 diabetes; the savings card is not available for Mounjaro prescribed off-label for weight loss (the Zepbound savings card covers that indication separately).
• The $25/month cap applies for up to 12 months per calendar year. After 12 months, Lilly typically renews enrollment, but the terms can change annually.

Patients activate the card at SavingsCard.Mounjaro.com, receive a PDF or physical card, and present it at the pharmacy alongside their insurance card. The savings card acts as a secondary payer, covering the copay or coinsurance gap down to $25. California pharmacies running on the most common PBM networks (CVS Caremark, Express Scripts, OptumRx) accept the card without issue. Some smaller independent pharmacies may need to process the card as a third-party claim; a call to the pharmacy in advance avoids delays at pickup.

Patients without insurance who are paying full cash price are not eligible for the $25 copay card but may qualify for Lilly's separate Insulin Value Program or, if income-eligible, the Lilly Cares Foundation program, which provides Mounjaro at no cost to uninsured patients with household income at or below 400% of the federal poverty level. In California, 400% FPL for a single-person household in 2026 is approximately $62,760 [9].

Telehealth Access to Mounjaro in California

California law permits a licensed prescriber to issue a valid Mounjaro prescription following a synchronous (real-time audio-video) telehealth visit without a prior in-person encounter. Assembly Bill 2485, enacted in 2022, codified that telehealth encounters meet the standard of care for establishing a prescriber-patient relationship in California when the visit includes adequate history-taking and clinical assessment [10].

A prescriber must still conduct a full clinical evaluation including weight, BMI, HbA1c or fasting glucose review, current medication list, and screening for contraindications (personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis) before initiating tirzepatide [1]. Prescribers who skip that evaluation and simply refill based on a patient-reported weight violate California Medical Board standards and expose themselves to discipline.

Mounjaro can be prescribed electronically (e-prescribe) to any California retail or specialty pharmacy, or to a mail-order pharmacy licensed in California. Most telehealth platforms operating in California send the prescription directly to the patient's preferred pharmacy via their state-licensed pharmacy network. Controlled-substance rules do not apply to Mounjaro because tirzepatide is not a scheduled substance.

The American Association of Clinical Endocrinologists 2023 Obesity Guidelines recommend considering GLP-1 or dual GIP/GLP-1 agonists for patients with BMI >30 kg/m2 or BMI >27 kg/m2 with at least one weight-related comorbidity [11]. Telehealth prescribers in California are bound by those same clinical thresholds; a prescription issued to a patient without meeting evidence-based criteria may be flagged during insurance audits or pharmacy utilization reviews.

Cheapest Way to Get Mounjaro in California: A Direct Comparison

Patients often ask which option actually saves the most money. The answer depends on insurance status and diagnosis, so a direct breakdown by patient type is most useful.

Type 2 diabetes, commercially insured, savings card eligible: The Eli Lilly savings card caps out-of-pocket cost at $25/month. No other option comes close for this group. Annual cost: $300.

Type 2 diabetes, Medi-Cal enrolled, PA approved: After PA approval, Medi-Cal cost-sharing for most enrollees is $0 to $3.65 per prescription fill. Annual cost: roughly $0 to $44.

Type 2 diabetes, uninsured, income above 400% FPL: Branded Mounjaro at cash price costs $1,023/month ($12,276/year). Compounded tirzepatide from a licensed California 503A pharmacy at $249/month ($2,988/year) is the lowest-cost legal option. A difference of $9,288 annually is substantial.

Type 2 diabetes, uninsured, income at or below 400% FPL: Lilly Cares Foundation may provide Mounjaro at no cost. Application processing takes 2 to 6 weeks; a prescriber letter of medical necessity is required.

Obesity only (no diabetes), commercially insured: Zepbound savings card offers $25/month if the plan covers Zepbound. If the plan excludes it, compounded tirzepatide at $249/month from a 503A pharmacy is the practical alternative while branded Mounjaro or Zepbound remains unaffordable.

A 2023 NEJM Perspective by Verma et al. estimated that widespread GLP-1/GIP coverage across commercial payers could reduce U.S. cardiovascular event costs by $1.4 billion annually, a figure that informed several ongoing state-level coverage mandates [12]. California has not yet passed a mandate requiring commercial plans to cover Mounjaro or Zepbound for obesity, though legislation (AB 1341) was introduced in the 2024-2025 session and remained in committee as of this writing.

Monitoring and Safety Considerations That Affect Cost Planning

Mounjaro is not a one-time prescription. Ongoing monitoring visits, lab work, and dose titration visits add to the total annual cost of treatment. Patients should budget for these.

Baseline labs before starting tirzepatide should include HbA1c, fasting glucose, comprehensive metabolic panel, lipid panel, and TSH (to screen for thyroid abnormalities relevant to the medullary thyroid carcinoma warning in the FDA label) [1]. A repeat HbA1c at 3 months quantifies glycemic response. Fasting glucose monitoring at home costs approximately $30 to $60 per month for test strips without insurance coverage.

Dose titration for Mounjaro follows a standard schedule: 2.5 mg once weekly for 4 weeks, then 5 mg once weekly. The prescriber may increase in 2.5 mg increments every 4 weeks based on tolerability and glycemic response, to a maximum of 15 mg once weekly [1]. Each titration step ideally involves a prescriber check-in, which costs $50 to $150 out-of-pocket for a telehealth visit without insurance.

The most common adverse effects reported in SURPASS-2 were nausea (17.4% at 15 mg), diarrhea (13.2%), and vomiting (9.5%) [3]. Gastrointestinal side effects are the primary reason patients discontinue during the titration phase, and discontinuation wastes medication already dispensed. Slower titration (staying at a given dose for 8 weeks rather than 4 weeks before increasing) may reduce GI burden and therefore reduce wasted medication cost, an approach supported by the SURPASS-3 tolerability subgroup analysis [13].

What California Patients Should Do Before Their First Prescription

Specific steps reduce cost and avoid delays.

First, verify insurance coverage before the prescription is sent to the pharmacy. Call the PBM and ask for the formulary tier, PA requirements, and whether step therapy applies. This call takes 15 minutes and can save weeks of back-and-forth.

Second, check eligibility for the Lilly savings card at SavingsCard.Mounjaro.com before the pharmacy visit, not at the pharmacy counter.

Third, if Medi-Cal is the payer, ask the prescriber to submit the PA at the time of the visit rather than after. Same-day PA submission shortens the wait by an average of 2 business days based on California DHCS processing data [4].

Fourth, if cost forces a compounding pharmacy route, verify the pharmacy license on BreEZe, request a CoA before accepting any vial, and confirm the pharmacy compounds under USP <797> sterile standards.

Fifth, confirm with the prescriber whether the intended indication on the prescription is type 2 diabetes (Mounjaro) or weight management (Zepbound), because the insurance billing path differs and misfiled claims are a common source of denial.

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean body weight reduction of 20.9% at 72 weeks versus 3.1% placebo (P<0.001) [14]. For patients with obesity and comorbidities, that magnitude of weight reduction has downstream effects on blood pressure, HbA1c, sleep apnea severity, and joint load, outcomes that may reduce other medication costs over time and should be factored into any conversation about the affordability of treatment.